Biomarkers as Key Contributors in Treating Malignant Melanoma Metastases
Melanoma is a human neurocristopathy associated with developmental defects in the neural crest-derived epidermal melanocytes. At the present time, at least three hypotheses were identified that may explain melanoma aetiology, as follows: (1) a model of linear progression from differentiated melanocy...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Dermatology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2012/156068 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832554506006560768 |
|---|---|
| author | Camila Ferreira de Souza Alice Santana Morais Miriam Galvonas Jasiulionis |
| author_facet | Camila Ferreira de Souza Alice Santana Morais Miriam Galvonas Jasiulionis |
| author_sort | Camila Ferreira de Souza |
| collection | DOAJ |
| description | Melanoma is a human neurocristopathy associated with developmental defects in the neural crest-derived epidermal melanocytes. At the present time, at least three hypotheses were identified that may explain melanoma aetiology, as follows: (1) a model of linear progression from differentiated melanocytes to metastatic cancer cells (2) a model involving the appearance of melanoma stem-like cells, and (3) an epigenetic progenitor model of cancer. Treating metastatic melanoma is one of the most serious challenges in the 21st century. This is justified because of a subpopulation of cells presenting a remarkable molecular heterogeneity, which is able to explain the drug resistance and the growing mortality rates worldwide. Fortunately, there are now evidences sustaining the importance of genetic, epigenetic, and metabolomic alterations as biomarkers for classification, staging, and better management of melanoma patients. To illustrate some fascinating insights in this field, the genes BRAFV600E and CTLA4 have been recognized as bona fide targets to benefit melanoma patients. Our research attempts to carefully evaluate data from the literature in order to highlight the link between a molecular disease model and the key contribution of biomarkers in treating malignant melanoma metastases. |
| format | Article |
| id | doaj-art-88511f83ef15428cad1880813d6ef49c |
| institution | Kabale University |
| issn | 1687-6105 1687-6113 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Dermatology Research and Practice |
| spelling | doaj-art-88511f83ef15428cad1880813d6ef49c2025-02-03T05:51:19ZengWileyDermatology Research and Practice1687-61051687-61132012-01-01201210.1155/2012/156068156068Biomarkers as Key Contributors in Treating Malignant Melanoma MetastasesCamila Ferreira de Souza0Alice Santana Morais1Miriam Galvonas Jasiulionis2Pharmacology Department, Federal University of São Paulo, 04039-032 São Paulo, SP, BrazilPharmacology Department, Federal University of São Paulo, 04039-032 São Paulo, SP, BrazilPharmacology Department, Federal University of São Paulo, 04039-032 São Paulo, SP, BrazilMelanoma is a human neurocristopathy associated with developmental defects in the neural crest-derived epidermal melanocytes. At the present time, at least three hypotheses were identified that may explain melanoma aetiology, as follows: (1) a model of linear progression from differentiated melanocytes to metastatic cancer cells (2) a model involving the appearance of melanoma stem-like cells, and (3) an epigenetic progenitor model of cancer. Treating metastatic melanoma is one of the most serious challenges in the 21st century. This is justified because of a subpopulation of cells presenting a remarkable molecular heterogeneity, which is able to explain the drug resistance and the growing mortality rates worldwide. Fortunately, there are now evidences sustaining the importance of genetic, epigenetic, and metabolomic alterations as biomarkers for classification, staging, and better management of melanoma patients. To illustrate some fascinating insights in this field, the genes BRAFV600E and CTLA4 have been recognized as bona fide targets to benefit melanoma patients. Our research attempts to carefully evaluate data from the literature in order to highlight the link between a molecular disease model and the key contribution of biomarkers in treating malignant melanoma metastases.http://dx.doi.org/10.1155/2012/156068 |
| spellingShingle | Camila Ferreira de Souza Alice Santana Morais Miriam Galvonas Jasiulionis Biomarkers as Key Contributors in Treating Malignant Melanoma Metastases Dermatology Research and Practice |
| title | Biomarkers as Key Contributors in Treating Malignant Melanoma Metastases |
| title_full | Biomarkers as Key Contributors in Treating Malignant Melanoma Metastases |
| title_fullStr | Biomarkers as Key Contributors in Treating Malignant Melanoma Metastases |
| title_full_unstemmed | Biomarkers as Key Contributors in Treating Malignant Melanoma Metastases |
| title_short | Biomarkers as Key Contributors in Treating Malignant Melanoma Metastases |
| title_sort | biomarkers as key contributors in treating malignant melanoma metastases |
| url | http://dx.doi.org/10.1155/2012/156068 |
| work_keys_str_mv | AT camilaferreiradesouza biomarkersaskeycontributorsintreatingmalignantmelanomametastases AT alicesantanamorais biomarkersaskeycontributorsintreatingmalignantmelanomametastases AT miriamgalvonasjasiulionis biomarkersaskeycontributorsintreatingmalignantmelanomametastases |